Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/4/2024 | $17.00 | Overweight | Wells Fargo |
9/5/2024 | $9.00 | Buy | Jefferies |
4 - aTYR PHARMA INC (0001339970) (Issuer)
4 - aTYR PHARMA INC (0001339970) (Issuer)
SC 13G - aTYR PHARMA INC (0001339970) (Subject)
SC 13G/A - aTYR PHARMA INC (0001339970) (Subject)
Wells Fargo initiated coverage of aTyr Pharma with a rating of Overweight and set a new price target of $17.00
Jefferies initiated coverage of aTyr Pharma with a rating of Buy and set a new price target of $9.00
SAN DIEGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the appointment of Jayant Aphale, Ph.D., as Vice President, Technical Operations. Dr. Aphale will serve as a member of the Company's executive leadership team, overseeing manufacturing activities at contract development and manufacturing organizations and implementing strategies related to the continuous improvement of commercial manufacturing, supply chain management, process development of new products and product lif
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will present at several upcoming investor conferences scheduled to take place in November and December 2024. Details of the conferences appear below: Conference: Stifel Healthcare ConferenceDate: Monday, November 18, 2024 Time: 3:35pm ESTLocation: New York, NYFormat: Corporate Presentation Conference: Jefferies London Healthcare Conference Date: Wednesday, November 20, 2024Time: 3:00pm GMTLocation: London, UKFormat: Cor
Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups. 54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compared to 7.7% in the therapeutic group. SAN DIEGO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a post hoc analysis of th
SAN DIEGO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the company will participate in several upcoming investor conferences scheduled to take place in September 2024. Details of the conferences appear below: Conference: Wells Fargo Healthcare ConferenceDate: Thursday, September 5, 2024 Location: Everett, MAFormat: 1x1 Investor Meetings Conference: H.C. Wainwright 26th Annual Global Investment Conference Date: Wednesday, September 11, 2024Time: 10:30am EDTLocation: New York, NYFormat: Corpor
S-8 - aTYR PHARMA INC (0001339970) (Filer)
10-Q - aTYR PHARMA INC (0001339970) (Filer)
8-K - aTYR PHARMA INC (0001339970) (Filer)
The Dow Jones index closed lower by over 500 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Super League Enterprise The Trade: Super League Enterprise, Inc. (NASDAQ:SLE) Director Jeff Patrick Gehl bought a total of 50,000 shares at an average price of $1.35. To acquire these shares, it cost around $67,548. What's Happening: On June
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma (NASDAQ:ATYR) with a Buy and maintains $35 price target.